Sucampo Reports Strong Results for First Quarter of 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Guggenheim Reiterates Buy on Sucampo Pharma (SCMP) Following 1Q Earnings
May 4, 2016 1:07 PM EDTGuggenheim reiterated a Buy rating and $29.00 price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) following the company's 1Q earnings report. SCMP reported 1Q16 diluted EPS of $0.21, in line with consensus. Management reiterated its '16 adjusted EPS guidance of $1.02 at the midpoint (consensus was $1.05).
Analyst... More
